|
|
|||||||
Acute Leukemia |
From the Department of Hematology and Bone Marrow Transplantation Unit, "V. Cervello" Hospital, Palermo, Italy (CA, FF, VR, LC, GC, AM, MLR, SM, AS); IFOM, Fondazione Istituto FIRC di Oncologia Molecolare, Milano, Italy (RB)
Correspondence: Alessandra Santoro, Laboratorio di, Ematologia, Divisione di Ematologia, e Unità Trapianti di Midollo Osseo, Ospedale V. Cervello, Via Trabucco, 180, 90146 Palermo, Italy. E-mail: santoro.al{at}libero.it
| ABSTRACT |
|---|
|
|
|---|
Key words: LOH, acute leukemia, recurrent chromosomal aberrations.
Clonal chromosomal abnormalities are detected by conventional cytogenetic analysis (CCA) in 40–60% of patients with de novo acute myeloid leukemia (AML).1 Thus, CCA is a fundamental component of modern leukemia cytogenetics. Nevertheless, cryptic chromosomal aberrations may escape CCA, only being detected by molecular genetic analysis. Loss of heterozygosity (LOH), resulting from deletion of one allele at a given locus, may be used as a marker of genetic imbalance in several neoplasms.2 Its ability to detect smaller DNA losses, in the range of a few kilobases, results in a higher resolution power than CCA and FISH. To identify patients who have submicroscopic deletions at various chromosomal regions, we performed a microsatellite allelotype assay based on fluorescence-PCR in 74 patients with AML.
| Design and Methods |
|---|
|
|
|---|
Karyotype was available in 63 of the 74 cases (85%). Twenty-five patients had a normal karyotype. Favorable cytogenetic alterations were found in 19 patients, such as t(8;21), t(15;17), and inv(16). Twelve patients had unfavorable alterations, such as –7/del(7q), 11q23, 3q abnormalities, t(6;9), hyperdiploidy and complex karyotype. Trisomy 8 as a single aberration was found in two patients, and the remaining 5 cases carried miscellaneous clonal abnormalities. Chromosomal abnormalities were classified according to the International System for Cytogenetic Nomenclature.4 The cytogenetic risk classification of AML patients was performed according to current criteria.5
Microsatellites analysis
Diagnostic samples from bone marrow and/or peripheral blood containing a high proportion of leukemic cells (>80%) were used for molecular studies. We used epithelial cells from buccal mucosa at diagnosis (8 pts), or T lymphocytes, from peripheral blood at clinical remission (66 patients) as a source of constitutional DNA for each patient. These were immunoselected using magnetic beads (MiniMacs; Miltenyi Biotec Bergish Gladbach, Germany). LOH was assessed by using oligonucleotide primers for 35 highly polymorphic microsatellite repeat markers chosen among those spanning chromosomal 5q31-32, 6q16-23, 7q22.1-33, 9q21.3-22, 12p12.2-13.3, 13q13, 17p12-13.3 and 20q11 (Figure 1). Commercial primers with fluorescent dye phosphoramidites FAM, TET or NED were used (Applied Biosystem, CA, USA). PCR-amplification of microsatellite sequences was performed and analyzed by capillary electrophoresis as previously described.6
|
|
| Results and Discussion |
|---|
|
|
|---|
Among the 42 cases with genetic imbalance, 9 had unfavorable cytogenetic (cases #1, 7, 15, 19, 31, 34, 36, 38 and 40), 9 patients (21%) had favorable cytogenetic (cases #10, 16, 21–26, 32), 10 patients (23%) showed a diploid karyotype (cases #3, 4, 6, 9, 12, 18, 27, 30, 33 and 39) and the remaining 6 patients showed miscellaneous chromosomal abnormalities (cases #8, 11, 14, 17, 20 and 41). Remarkably, all chromosomal monosomies or deletions (cases #1, 14, 17, and 40) have been confirmed by the microsatellites data, whereas 38 cases with genetic imbalance had no cytogenetically detectable abnormalities at the screened bands. Our data suggest that LOH is a common event in adults with acute myeloid leukemia, involving at least one half of patients. This percentage may be an underestimation since we used a restricted panel of microsatellites. The percentage of patients with LOH may significantly increase if a broader panel is used.
Possible advances in the treatment of acute leukemia also depend on understanding the pathogenic mechanisms. Identification of genetic events which facilitate or start the leukemic process represents a major objective of current research in this field. If one assumes that LOH may impact on the mechanisms of leukemogenesis, definition of its real frequency is of interest. Nevertheless the incidence of LOH in de novo acute leukemia remains controversial, since only limited data are available. In the only reported genome-wide screening study of childhood AML, microsatellite LOH was found in 17 out of 53 samples (32%).7 Although a very small series, 80% of LOH was found in childhood acute lymphoblastic leukemia by using genome-wide arrays of single nucleotide polymorphisms (SNP).8 Very few data are reported in adult AML. Pabst et al.9 showed microsatellite LOH in 25/32 (78%) patients, and Gorletta et al.10 in 20% patients with normal karyotype. Altogether, these data confirm that LOH is a frequent finding in acute leukemia and discrepancies in its incidence may be related to different techniques.
It has recently been suggested that LOH arises not only from chromosomal deletion, but also from somatic recombination with acquired uniparental dysomy (UPD).11 This results in large homozygous regions spanning from a specific point to the telomere. This novel form of abnormality was documented by genome-wide SNP analysis in about 20% of AML by Raghavan et al.11 UPD mechanism could explain LOH only in a minority of our patients (cases #5, 11, 12, 39 and 42) while the remaining had interstitial LOH, compatible only with loss of genetic material. This agress with the findings of Gorletta et al.10
In our series, LOH was not apparently restricted to, or associated with, any specific AML FAB subtype or chromosomal region, with the only exception of the 7q band, which was involved in 10 cases with normal chromosome 7 at CCA. Conflicting results have been reported on the 7q region involvement in patients with cytogenetically normal chromosome 7. In a previous series, we found 7q LOH in 16 of 50 (32%) cases of acute leukemia, including 13 cases which were LOH+ve despite cytogenetically normal chromosome 7. In this series, submicroscopic deletions at D7S486 were confirmed by FISH.6
What has been learned from the comparative study of conventional cytogenetic and molecular data? Submicroscopic deletions, which may be detected by FISH, have been reported proximal to the translocation breakpoints of some non-random leukemia-associated translocation.12,13 This suggests that the underlying mechanism is likely to be associated with the translocation process itself and may be dependent on the flanking sequences. No deletions were found in adult AML with normal karyotype by Cuneo et al.14 In a 24-color FISH study, Schoch et al.15 showed that loss of genetic material is a frequent event in AML with a complex aberrant karyotype. Furthermore, a large spectrum of genomic imbalances were identified in a recent study using comparative genomic hybridization array (array-CGH).16 The frequency of LOH may depend heavily on the methods used for its screening. Novel techniques such as array-based SNP and CGH allow a high resolution screening and confirm that cryptic chromosomal abnormalities are a common event in leukemia.
In conclusion, on the basis of our findings, LOH appears to be a very common event in adult AML, not associated with recurrent chromosomal alterations, and may also be found in patients with diploid karyotype. LOH may occur not only adjacent to usual breakpoint regions, but also some distance from them, suggesting that loss of chromosomal material occurring throughout the genome may be a pivotal mechanism for leukemogenesis. Cryptic deletions may cause homozygosity of tumor-suppressor genes and may influence gene expression pattern by loss of microRNA or as a consequence of gene dosage.17,18 Moreover, LOH due to acquired uniparental dysomy has been associated with homozygous gene mutation in AML.19 All of these mechanisms may have important implications in leukemogenesis. Whether LOH is a primary event or a secondary molecular lesion remains to be clarified.
| Acknowledgments |
|---|
| Footnotes |
|---|
CA and RB contributed equally to this work. They performed the LOH study and contributed to the discussion of results; FF is involved in clinical management of acute leukemia. He addressed the leukemic samples to the Laboratory of Hematology and contributed to the discussion of results; VR and LC performed standard cytogenetic and FISH analysis and contributed to the discussion of results; GC and MLR were involved in molecular investigation and contributed to the discussion of results; AM performed the diagnostic Immunophenotype analysis of leukemic blasts by flow-cytometry; SM, the Head of the Division, was in charge of clinical assistance; he contributed to the study design and partially to funding the study; AS the principal Investigator, was responsible for the main study design. She overviewed the research plan from its design to development, was responsible for the analysis of the results, and drafted the manuscript.
The authors reported no potential conflicts of interest.
Funding: this work was in part supported by a grant from the Associazione Italiana per la Ricerca sul Cancro (AIRC) and Associazione Italiana contro le Leucemie (AIL).
Received for publication November 13, 2006. Accepted for publication March 8, 2007.
| References |
|---|
|
|
|---|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | TABLE OF CONTENTS | ARCHIVE | SUBSCRIPTIONS |